| Identification | Back Directory | [Name]
LF163892 MONOHYDRATE | [CAS]
76470-66-1 | [Synonyms]
Lorabid
LOEACARBEF
LORACARBEF
LF163892 MONOHYDRATE
LORACARBEF MONOHYDRATE
LF163892 MONOHYDRATE USP/EP/BP
3-Chloro-7β-[[(R)-aminophenylacetyl]amino]-1-carbacepham-3-ene-4-carboxylic acid
(6R)-7α-[[(R)-Aminophenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,6β)-7α-[[(R)-Aminophenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7S)-7-[[(2R)-2-AMino-2-phenylacetyl]aMino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid
1-Azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid, 7-[[(2R)-2-aMino-2-phenylacetyl]aMino]-3-chloro-8-oxo-, (6R,7S)-
(6R,7S)-7-{[(2R)-2-Ammonio-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, monohydrate | [EINECS(EC#)]
617-954-4 | [Molecular Formula]
C16H16ClN3O4 | [MOL File]
76470-66-1.mol | [Molecular Weight]
349.77 |
| Hazard Information | Back Directory | [Description]
Loracarbef is a synthetic C-5 “carba” analogue of cefaclor. The smaller methylene moiety (as compared to
sulfur) would be expected to make loracarbef more reactive/potent, and this seems to be the case. It is more
stable chemically, however, and this adds to its virtues. | [Originator]
Lorabid,Eli Lilly and Company | [Uses]
An antibiotic, a synthetic carbacephem analogue of cefaclor, and is more stable chemically. | [Definition]
ChEBI: A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria. | [Manufacturing Process]
Loracarbef was obtained by biochemical method.
a) Cultivation of a microorganism having an ability of optically selective
acylation
As a seed strain, Pseudomonas melanogenum ATCC 17808 [Biological
properties are described in Journal of the Agricultural Chemical Society of
Japan 37, 71 (1963)] is used.
As the seed medium, an aqueous solution containing 1% polypepton, 1%
yeast extract, 0.5% meat extract, 0.5% sodium glutamate and 0.25% sodium
chloride and adjusted to a pH of 7.0 with 5 N NaOH is used. One loopful of
the seed strain is inoculated into 10 ml the seed medium and culturing is
carried out at of 30°C for 24 hours. The whole amount of the seed medium is
put into 300 ml of the culture medium in a 2 L Erlenmeyer flask and culturing
is carried out at a temperature of 30°C. The composition of the culture
medium is the same as that of the seed medium.
b) Preparation of cell suspension
After culturing for 24 hours, cell bodies are recovered from the culture broth
by centrifugation and washed 2 times with 50 ml of 0.9% saline solution. The
cells are suspended in a concentration of 20 mg/ml by dry weight in 1/30 M
phosphate buffer (pH 6.5).
c) Preparation of a substrate solution
200 mg of the trifluoroacetate of ()-cis-7-amino-3-chloro-1-azabicyclo[4,2,0]
oct-2-en-8-on-2-carboxylic acid (obtained by the method described in JPUPA
No. 87791/80) and 800 mg of the hydrochloride of D-phenylglycine
methylester are added in 9 ml of 1/30 M potassium phosphate buffer (pH6.5). 5 N KOH is added in a small portion and the mixture is again adjusted to
a pH of 6.5 to dissolve two starting compounds. Finally, deionized water is
added to make 10 ml of a solution.
d) Enzyme reaction
In this step, 10 ml of the disrupted cell suspension is added to 10 ml of the
substrate solution and enzyme reaction is carried out at a temperature of
30°C for 2 hours. The reaction is monitored by high speed liquid
chromatography. Elution is carried out with 7% methanol - 0.2 M KH2PO4
solution. Reaction reaches maximum in a yield of 90% to the starting
compound in 2 hours.
After the completion of reaction, cell bodies are removed from the reaction
solution by centrifugation. The supernatant is concentrated under reduced
pressure and charged on a column with 100 ml of Diaion HP-10. After adding
200 ml of deionized water, elution is carried out with 25% aqueous methanol
solution. Then, the fractions containing the desired compound are
concentrated under reduced pressure to make a 5 ml of concentrate. The
concentrate is charged on a column packed with 130 ml of Sephadex-LH20
and elution is carried out with a solvent of water and methanol (50:50). The
desired product is eluted in 55 ml to 75 ml of fractions. The fractions are
concentrated under reduced pressure and lyophilized to obtain 78 mg
(6R,7S)-7-(R)-phenylglycinamido-3-chloro-1-azabicyclo[4,2,0]oct-2-en-8-on-
2-carboxylic acid of a white powder [α]D21 = -75.8° (c = 0.4, H2O), melting
point 300°C or more (browning). | [Brand name]
Lorabid (King). | [Therapeutic Function]
Antibiotic | [Antimicrobial activity]
An oral carbacephem, with carbon replacing sulfur in the
fused ring structure. Its structure and properties are otherwise
closely related to those of cefaclor, but it has improved
chemical stability. Activity and stability to β-lactamases correspond
closely to those of cefaclor.
It is almost completely absorbed by the oral route, but
food delays absorption. A 500 mg oral dose achieves a serum
concentration of around 16 mg/L after 1.3 h. Adequate concentrations
are achieved for the treatment of upper respiratory
tract infection. Sputum concentrations have been found
to be around 2% of the corresponding plasma level. The
plasma half-life is about 1 h and protein binding is 25%.
Most of the dose is excreted unchanged in the urine, 60%
within 12 h. The elimination half-life is increased in patients
with impaired renal function. Probenecid delays excretion.
Diarrhea is the most prominent side effect, occurring in
about 4% of patients. Other gastrointestinal upsets are also
reported. It has been used for the oral treatment of upper
respiratory tract infection, skin and soft-tissue infections, and
uncomplicated urinary tract infection caused by sensitive
organisms, but is not widely available. | [Clinical Use]
Loracarbef (Lorabid) is the first of a series of carbacephemsprepared by total synthesis to be introduced. Carbacephemsare isosteres of the cephalosporin (or △ 3-cephem) antibioticsin which the 1-sulfur atom has been replaced by a methylene(CH2) group. Loracarbef is isosteric with cefaclor and hassimilar pharmacokinetic and microbiological properties.Thus, the antibacterial spectrum of activity resembles thatof cefaclor, but it has somewhat greater potency againstH. influenzae and M. catarrhalis, including β-lactamase–producing strains. Unlike cefaclor, which undergoes degradationin human serum, loracarbef is chemically stable inplasma. It is absorbed well orally. Oral absorption is delayedby food. The half-life in plasma is about 1 hour. | [Side effects]
Diarrhea is the most common adverse effect with
loracarbef and, along with certain other adverse effects, is seen more frequently with children, so this
lessens enthusiasm for the drug in patients younger than 12 years. |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|